GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PhotoCure ASA (OTCPK:PHCUF) » Definitions » Forward PE Ratio

PhotoCure ASA (PhotoCure ASA) Forward PE Ratio : 0.00 (As of Jun. 24, 2024)


View and export this data going back to . Start your Free Trial

What is PhotoCure ASA Forward PE Ratio?

PhotoCure ASA's Forward PE Ratio for today is 0.00.

PhotoCure ASA's PE Ratio without NRI for today is 341.67.

PhotoCure ASA's PE Ratio for today is 341.67.


PhotoCure ASA Forward PE Ratio Historical Data

The historical data trend for PhotoCure ASA's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhotoCure ASA Forward PE Ratio Chart

PhotoCure ASA Annual Data
Trend 2015-12 2016-09 2017-12 2018-12 2019-12 2020-12 2021-06
Forward PE Ratio
86.21 212.77 53.48 39.06 46.95 81.97 126.58

PhotoCure ASA Quarterly Data
2015-12 2017-09 2017-12 2018-03 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03 2020-09 2020-12 2021-03 2021-06
Forward PE Ratio 86.21 107.53 53.48 52.08 27.62 39.06 34.97 149.25 36.10 46.95 57.47 79.37 81.97 117.65 126.58

Competitive Comparison of PhotoCure ASA's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhotoCure ASA's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where PhotoCure ASA's Forward PE Ratio falls into.



PhotoCure ASA Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


PhotoCure ASA  (OTCPK:PHCUF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


PhotoCure ASA Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of PhotoCure ASA's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PhotoCure ASA (PhotoCure ASA) Business Description

Traded in Other Exchanges
Address
Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products specialty pharmaceutical companies. Its technology platform is focused on the field of photodynamic diagnosis and treatment of cancer. It has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, Netherlands, Other European countries, and the United States.